登录

Cytovant Sciences Announces $23.5 Million Financing Led by BNH Investment

作者: Mailman 2020-04-07 09:02
鸿声医药
http://www.cytovant.com/
企业数据由 动脉橙 提供支持
创新细胞疗法开发商 | 战略融资 | 运营中
中国-上海
2020-04-03
融资金额:$2350万
BNH Investment
查看

According to PRNewswire.com, Cytovant Sciences ("Cytovant"), a biopharmaceutical company founded by Roivant Sciences focused on developing and commercializing innovative cellular therapeutics in Asia, has announced the completion of a fundraising round with a US$23.5 million investment from BNH Investment, POSCO Capital, Mirae Asset Venture Investment, Smilegate Investment, and other leading Korean healthcare and venture capital investors.


Cytovant is a clinical-stage biopharmaceutical company focused on developing innovative cellular therapeutics in Asia. Cytovant's technology platform is built on complementary immunotherapeutic approaches, including TCR-transgenic T-cell (TCR-T) and dendritic cell (DC) vaccine therapeutics.


Cytovant's lead cell therapy program for the treatment of acute myeloid leukemia (AML), CVT-DC-01, is based on DC vaccine technology in-licensed from Medigene in April 2019. Medigene recently reported positive topline data from a Phase 1/2 study in which 20 AML patients were treated with their DC vaccine FDC101 for 24 months following induction or consolidation therapy. Treatment with the vaccine was shown to be feasible, safe and well-tolerated over the 2-year treatment period.


Cytovant intends to use the proceeds of this funding round to advance both CVT-DC-01 and its lead TCR-T candidate, CVT-TCR-01, into the clinic in Asia.


"Asian patients have unique immunologic features and are treated in healthcare systems that may differ markedly from their Western counterparts. Our strategy is to develop treatments to address those needs precisely," said Dr. John Xu, President of Cytovant. "This financing will rapidly accelerate the development of our medicines for patients in China, Korea, and Japan."


>>>>

About Mirae Asset Venture Investment (Mirae Asset)


Mirae Asset invests in specialized enterprises and provides technology, funding and management consulting. With a fundamental investment philosophy of "Building on principles", Mirae Asset.has become Asia's premier financial group and created new trends in the Asian capital market.


>>>>

About Smilegate Investment


Smilegate Investment, founded in 1999 originally as MVP Capital, is a venture capital and private equity firm that has been growing remarkably alongside its invested companies. From its initial venture capital funding in 2000, the company has since organized and managed more than 30 venture capital and private equity funds, and has invested in more than 200 companies with promising growth potential.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

谷歌风投、OrbiMed等多家顶级投资机构,他们在海外投什么医疗企业

Legend Biotech Receives $150 Strategic Investment

ImmuneOnco Snares ¥45M in Pre-B Round of Financing, Focusing on Cancer Immunotherapy

GenCells Therapeutics Completes ¥10M Pre-A Round of Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

2020年健康险继续火爆:重磅政策出台,VC逆势加仓,数笔融资破亿

2020-04-07
下一篇

KFBIO Closes on Series B Funding Round

2020-04-07